Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 5/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689725 | 1.00 | RAF1 (0.39) | RAF1TRPV1ABL1CNR2SCN10A | |
| SCHEMBL19689799 | 0.92 | RAF1 (0.38) | RAF1TRPV1SCN10A | |
| SCHEMBL17778714 | 0.92 | RAF1 (0.38) | RAF1TRPV1SCN10A | |
| SCHEMBL19689800 | 0.92 | RAF1 (0.38) | RAF1TRPV1SCN10A | |
| SCHEMBL17767972 | 0.92 | RAF1 (0.38) | RAF1TRPV1SCN10A | |
| SCHEMBL19689828 | 0.89 | RAF1 (0.36) | RAF1TRPV1 | |
| SCHEMBL19689829 | 0.89 | RAF1 (0.36) | RAF1TRPV1 | |
| SCHEMBL20720919 | 0.88 | RAF1 (0.37) | RAF1TRPV1CNR2 | |
| SCHEMBL17778595 | 0.88 | RAF1 (0.37) | RAF1TRPV1CNR2 | |
| SCHEMBL17769296 | 0.88 | RAF1 (0.37) | RAF1TRPV1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RAF1 2078/4885TRPV1 4032/4885ABL1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.